<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04300998</url>
  </required_header>
  <id_info>
    <org_study_id>19-452</org_study_id>
    <nct_id>NCT04300998</nct_id>
  </id_info>
  <brief_title>Study of CAR-T Therapy in Older Patients</brief_title>
  <official_title>Observational Study of Commercial Chimeric Antigen Receptor T-cell (CAR T) Therapy in Older Patients With Hematologic Malignancies and With an Embedded Pilot Study of Longitudinal Geriatric and Neurocognitive Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to find out how older patients respond to CAR-T cell therapy and how&#xD;
      the treatment affects their quality of life. This is a quality of life study and&#xD;
      participating in the study does not involve receiving any treatment, other than the standard&#xD;
      treatment for participants' disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 4, 2020</start_date>
  <completion_date type="Anticipated">March 4, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 4, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who complete all required assessment visits prior to disease progression or death</measure>
    <time_frame>1 year</time_frame>
    <description>Participants who complete all assessment visits prior to disease progression or death will be considered as a success for a feasibility endpoint.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">178</enrollment>
  <condition>Lymphoma</condition>
  <condition>Refractory B-Cell Lymphoma</condition>
  <condition>Lymphoma, B-Cell</condition>
  <condition>DLBCL NOS</condition>
  <condition>High-grade B-cell Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>older lymphoma patients</arm_group_label>
    <description>This is a prospective observational cohort where 18 older patients (≥60yo) undergoing CAR T therapy for relapsed refractory high-grade B-cell lymphoma will undergo serial comprehensive geriatric assessment, neurocognitive testing, and quality of life evaluation prior to and following CAR T therapy. The standard follow-up period is one year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>older patients with lymphoma and other lymphoid malignancies</arm_group_label>
    <description>This is a prospective observational cohort where 100 older patients (≥60yo) undergoing CAR T therapy for relapsed refractory lymphoma and lymphoid malignancies will undergo comprehensive geriatric assessment, aging biomarker analysis, and quality of life evaluation prior to and following CAR T therapy. The standard follow-up period is one year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>older patients with myeloma and other plasma cell disorders</arm_group_label>
    <description>This is a prospective observational cohort where 60 older patients (≥60yo) undergoing CAR T therapy for relapsed refractory plasma cell disorders will undergo</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Activities of Daily Living/ADLs</intervention_name>
    <description>7 activities: bathing, dressing, grooming, feeding, walking inside the home, walking outside the home, and bladder and bowel control. Participants get 2 points for each activity that is not limited at all, 1 point for limited a little, and 0 points for limited a lot. Total ADL score ranges from 0 to 14</description>
    <arm_group_label>older lymphoma patients</arm_group_label>
    <arm_group_label>older patients with lymphoma and other lymphoid malignancies</arm_group_label>
    <arm_group_label>older patients with myeloma and other plasma cell disorders</arm_group_label>
    <other_name>ADLs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Instrumental Activity of Daily Living</intervention_name>
    <description>8 activities: telephone use, doing laundry, shopping, preparing meals, doing housework, handling own medications, handling money and finances, and transportation to visit one's doctor. Participants get 2 points for each activity that can be done without help, 1 point for needing some help, and 0 point for being unable to do. Total iADL score ranges from 0 to16.</description>
    <arm_group_label>older lymphoma patients</arm_group_label>
    <arm_group_label>older patients with lymphoma and other lymphoid malignancies</arm_group_label>
    <arm_group_label>older patients with myeloma and other plasma cell disorders</arm_group_label>
    <other_name>iADLS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Timed Up and Go</intervention_name>
    <description>Participants are asked to get up from the chair, walk 10 feet, turn, and walk back to the char (&lt;10 seconds, 10-20 seconds, &gt;20 seconds)</description>
    <arm_group_label>older lymphoma patients</arm_group_label>
    <arm_group_label>older patients with lymphoma and other lymphoid malignancies</arm_group_label>
    <arm_group_label>older patients with myeloma and other plasma cell disorders</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognition</intervention_name>
    <description>Mini-Cognition test: CDT and 3-word recall</description>
    <arm_group_label>older lymphoma patients</arm_group_label>
    <arm_group_label>older patients with lymphoma and other lymphoid malignancies</arm_group_label>
    <arm_group_label>older patients with myeloma and other plasma cell disorders</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Geriatric Depression Scale</intervention_name>
    <description>Four yes/no questions regarding patient's psychological status. Score ranges from 0 to 4, and a score of &gt;/=1 is usually indicative of depression.</description>
    <arm_group_label>older lymphoma patients</arm_group_label>
    <arm_group_label>older patients with lymphoma and other lymphoid malignancies</arm_group_label>
    <arm_group_label>older patients with myeloma and other plasma cell disorders</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Social Support</intervention_name>
    <description>Four 5-point Likert scale questions addressing 4 domains of social support: emotional/ informational, tangible, affectionate, and positive social interaction. Score for each item ranges from 1 to 5, and total score ranges from 4 to 20. A higher score means better social support.</description>
    <arm_group_label>older lymphoma patients</arm_group_label>
    <arm_group_label>older patients with lymphoma and other lymphoid malignancies</arm_group_label>
    <arm_group_label>older patients with myeloma and other plasma cell disorders</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Brief Test of Attention</intervention_name>
    <description>assess selective auditory attention.</description>
    <arm_group_label>older lymphoma patients</arm_group_label>
    <arm_group_label>older patients with lymphoma and other lymphoid malignancies</arm_group_label>
    <arm_group_label>older patients with myeloma and other plasma cell disorders</arm_group_label>
    <other_name>BTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Trail Making Test</intervention_name>
    <description>Assesses visual scanning, graphomotor speed, and set shifting.</description>
    <arm_group_label>older lymphoma patients</arm_group_label>
    <arm_group_label>older patients with lymphoma and other lymphoid malignancies</arm_group_label>
    <arm_group_label>older patients with myeloma and other plasma cell disorders</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Controlled Oral Word Association Test</intervention_name>
    <description>A timed test of verbal fluency</description>
    <arm_group_label>older lymphoma patients</arm_group_label>
    <arm_group_label>older patients with lymphoma and other lymphoid malignancies</arm_group_label>
    <arm_group_label>older patients with myeloma and other plasma cell disorders</arm_group_label>
    <other_name>COWAT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Hopkins Verbal Learning Test-Revised</intervention_name>
    <description>The HVLT-R is a test of verbal learning and recall. Scores obtained are the total number of words: 1) recalled over three trials; 2)recalled after a delay; 3) correctly recognized.</description>
    <arm_group_label>older lymphoma patients</arm_group_label>
    <arm_group_label>older patients with lymphoma and other lymphoid malignancies</arm_group_label>
    <arm_group_label>older patients with myeloma and other plasma cell disorders</arm_group_label>
    <other_name>HVLT-R</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>collection of blood tests</description>
    <arm_group_label>older patients with lymphoma and other lymphoid malignancies</arm_group_label>
    <arm_group_label>older patients with myeloma and other plasma cell disorders</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited from all oncologists and all transplant physicians at the&#xD;
        Memorial Sloan Kettering Cancer Center. Patients are recruited without consideration of&#xD;
        gender, country of origin, educational level, or income. There will be no reimbursement or&#xD;
        payment toward the participation of this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  are ≥60 years old (all cohorts)&#xD;
&#xD;
          -  have pathologically confirmed, relapsed refractory lymphoid malignancy or plasma cell&#xD;
             disorder receiving a commercial CAR T-cell product (all cohorts)&#xD;
&#xD;
          -  able to speak and understand English (cohort 1 only)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any prior commercial or investigational CAR T therapy (all cohorts)&#xD;
&#xD;
          -  Current diagnosis of major Axis I psychiatric disorder (DSM-IV), major depression,&#xD;
             bipolar disorder, or schizophrenia, as per medical records or patient report (cohort 1&#xD;
             only)&#xD;
&#xD;
          -  History of a neurological disorder, neurodegenerative disease, or traumatic brain&#xD;
             injury with loss of consciousness (&gt;60 minutes), as per medical records or patient&#xD;
             report (cohort 1 only)&#xD;
&#xD;
          -  Current ongoing substance abuse and/or history of substance abuse, as per medical&#xD;
             records or patient report (cohort 1 only)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Lin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard Lin, MD, PhD</last_name>
    <phone>646-608-2646</phone>
    <email>linr@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sergio Giralt, MD</last_name>
    <phone>646-608-3731</phone>
    <email>GiraltS@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Lin, MD, PhD</last_name>
      <phone>646-608-2646</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 5, 2020</study_first_submitted>
  <study_first_submitted_qc>March 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2020</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>CART therapy</keyword>
  <keyword>relapsed refractory large B-cell lymphoma</keyword>
  <keyword>High-grade B-cell Lymphoma</keyword>
  <keyword>DLBCL NOS</keyword>
  <keyword>Refractory B-Cell Lymphoma</keyword>
  <keyword>19-452</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

